A Phase 2, Open Label, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of CM-101 Administered for 12 Weeks in Adult Subjects with Primary Sclerosing Cholangitis
Latest Information Update: 22 May 2025
At a glance
- Drugs CM 101 (Primary)
- Indications Primary sclerosing cholangitis
- Focus Proof of concept; Therapeutic Use
- Acronyms SPRING
- Sponsors Chemomab Therapeutics
Most Recent Events
- 15 May 2025 According to a Chemomab Therapeutics media release, data from this study presented as posters at EASL 2025
- 05 May 2025 According to a Chemomab Therapeutics media release, data from this study was presented at the Distinguished Abstract Plenary session at Digestive Disease Week (DDW 2025) in San Diego, California.
- 28 Apr 2025 Results published in the Media Release